Detalhe da pesquisa
1.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Int J Cancer
; 154(5): 863-872, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37840339
2.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35637412
3.
Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Int J Cancer
; 149(6): 1322-1331, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019698
4.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Br J Cancer
; 124(3): 587-594, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33154570
5.
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
BMC Cancer
; 21(1): 1239, 2021 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794396
6.
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
Ann Surg Oncol
; 27(7): 2389-2401, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32172334
7.
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Anticancer Drugs
; 31(8): 856-865, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32639280
8.
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Int J Cancer
; 140(8): 1918-1925, 2017 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28032641
9.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27575024
10.
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Eur J Cancer
; 201: 113926, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38401449
11.
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Clin Cancer Res
; 30(7): 1256-1263, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38289994
12.
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).
Oncol Res Treat
; 47(6): 251-261, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38565089
13.
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Eur J Cancer
; 178: 37-48, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399909
14.
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Eur J Cancer
; 190: 112955, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37454537
15.
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer.
Curr Oncol
; 30(6): 5828-5834, 2023 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366919
16.
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
J Clin Oncol
; 41(16): 2975-2987, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37018649
17.
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).
J Clin Oncol
; 40(1): 72-82, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34533973
18.
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
Eur J Cancer
; 173: 297-306, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35970102
19.
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
Eur J Cancer
; 173: 194-203, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35940054
20.
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.
Cancers (Basel)
; 14(3)2022 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158793